

## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Benjamin Lebwohl, M.D., M.S.

Committee: Joint meeting of the Gastrointestinal Drugs Advisory Committee (GIDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM)

Meeting Date: October 17, 2018

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: supplemental new drug application (sNDA) 021200, supplement 015, for tegaserod maleate (ZELNORM) tablets for oral administration, submitted by Sloan Pharma S.a.r.l, Bertrange, Cham Branch, proposed for the treatment of women with irritable bowel syndrome with constipation who do not have a history of cardiovascular ischemic disease, such as myocardial infarction, stroke, transient ischemic attack, or angina, and who do not have more than one risk factor for cardiovascular disease, I may be considered for participation in the advisory committee meeting described above.

Type of Interest	Nature	Magnitude
I. Personal/Immediate Family		
Stocks/investments	healthcare sector mutual fund	Between \$200,000-\$300,000
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of this interest, I will not participate in the advisory committee meeting described above.

/S/	9/22/2018
Signature	Date